Business
Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation
MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel
About this update from Veru Inc.
[{"type":"text","content":"MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that the clinical results from its Phase 1b/2 study of VERU-111 have been accepted for oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to be held September 19-21, 2020. VERU-111 is a novel, oral, first-in-class, tubulin targeting agent that crosslinks and disrupts alpha and beta tubulin subunits of microtubules. VERU-111 is in clinical development to treat metastatic castration and novel androgen receptor targeting agent (enzalutamide or abiraterone) resistant prostate cancer, a growing unmet medical need in advanced prostate cancer.\n Presentation details: Abstract Title: Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer who failed an androgen blocking agent Presenter: Mark Markowski, MD, PhD, Assistant Professor of Oncology, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Abstract Number: 2863 Additional information on the meeting can be found on the ESMO website https://www.esmo.org/meetings/esmo-virtual-congress-2020. “We are looking forward to sharing the clinical results evaluating VERU-111 in a Phase 1b/2 trial in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer,” said Mitchell Steiner, MD, Chairman, President and CEO of Veru Inc. “The presentation will focus on the clinical data from the Phase 1b clinical study. The ongoing Phase 2 clinical study portion has almost completed enrollment.” About Veru Inc.Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules. VERU-111 is being evaluated in an open label Phase 1b/Phase 2 clinical study in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer. The Phase 1b clinical study completed enrollment of 39 men and is ongoing. The Phase 2 clinical...